SLS-009 (Sellas Life Sciences Group)

Phase 2a trial demonstrates promising 67% overall response rate for tambiciclib plus zanubrutinib combination in relapsed/refractory DLBCL patients, including one complete response.

SELLAS Life Sciences anticipates a pivotal 2025 with key clinical milestones for its hematologic malignancy therapies, including data readouts and regulatory feedback.

Tyra Biosciences reported positive interim Phase 1/2 data for TYRA-300 in metastatic urothelial cancer (mUC), with a 54.5% confirmed partial response rate in FGFR3+ patients.

The Independent Data Monitoring Committee (IDMC) recommended continuing SELLAS Life Sciences' Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML).

SELLAS Life Sciences reports that SLS009, a CDK9 inhibitor, shows promising results in a Phase 2 trial for relapsed/refractory AML.